WallStSmart

Agilent Technologies Inc (A)vsQiagen NV (QGEN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 238% more annual revenue ($7.07B vs $2.09B). QGEN leads profitability with a 20.3% profit margin vs 18.3%. QGEN appears more attractively valued with a PEG of 1.00. QGEN earns a higher WallStSmart Score of 69/100 (B-).

A

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.99

QGEN

Strong Buy

69

out of 100

Grade: B-

Growth: 4.7Profit: 7.5Value: 10.0Quality: 6.8
Piotroski: 5/9Altman Z: 2.58
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-318.5%)

Margin of Safety

-318.5%

Fair Value

$30.80

Current Price

$112.98

$82.18 premium

UndervaluedFair: $30.80Overvalued
QGENUndervalued (+40.2%)

Margin of Safety

+40.2%

Fair Value

$85.35

Current Price

$40.63

$44.72 discount

UndervaluedFair: $85.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Return on EquityProfitability
20.0%9/10

Every $100 of equity generates 20 in profit

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

QGEN5 strengths · Avg: 8.2/10
Profit MarginProfitability
20.3%9/10

Keeps 20 of every $100 in revenue as profit

PEG RatioValuation
1.008/10

Growing faster than its price suggests

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

EPS GrowthGrowth
21.9%8/10

Earnings expanding 21.9% YoY

Areas to Watch

A3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

QGEN1 concerns · Avg: 4.0/10
Revenue GrowthGrowth
3.7%4/10

3.7% revenue growth

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.19 suggests the stock is reasonably priced for its growth.

Bull Case : QGEN

The strongest argument for QGEN centers on Profit Margin, PEG Ratio, Price/Book. Profitability is solid with margins at 20.3% and operating margin at 27.4%. PEG of 1.00 suggests the stock is reasonably priced for its growth.

Bear Case : A

The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.

Bear Case : QGEN

The primary concerns for QGEN are Revenue Growth.

Key Dynamics to Monitor

A profiles as a mature stock while QGEN is a value play — different risk/reward profiles.

A carries more volatility with a beta of 1.31 — expect wider price swings.

A is growing revenue faster at 7.0% — sustainability is the question.

A generates stronger free cash flow (175M), providing more financial flexibility.

Bottom Line

QGEN scores higher overall (69/100 vs 61/100), backed by strong 20.3% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Qiagen NV

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.

Visit Website →

Want to dig deeper into these stocks?